期刊文献+

应用HPLC-MS/MS法测定骨髓移植患者的血浆伏立康唑浓度 被引量:2

Determination of concentration of voriconazole in patients with bone marrow transplantation by HPLC-MS/MS
原文传递
导出
摘要 目的 建立测定骨髓移植患者血浆伏立康唑浓度的HPLC-MS/MS法,并应用于临床药物监测.方法 HPLC色谱柱为Ultimate XB-C18.柱温50℃,流速0.8 ml/min,流动相为含0.1%甲酸和2 mmol/L乙酸铵的水和含0.1%甲酸的甲醇,梯度洗脱.质谱检测方式为ESI正离子模式,多反应检测(MRM)扫描监测伏立康唑,用于定量分析的离子反应为:质荷比(m/z)350.1~281.2,用于定性分析的离子反应为:m/z 350.1~127.1;内标伏立康唑-d3 m/z 353.2~284.2.结果 伏立康唑浓度在0.1~10.0μg/ml时与峰面积线性关系良好(r=0.9991),日内及日间相对标准差(RSD)〈5%,平均回收率为88% ~103%.结论 本方法简便、准确、快速,适用于伏立康唑的血药浓度测定. Objective To establish the HPLC-MS/MS method for determination of voriconazole in bone marrow transplant patients, and use it in clinic trial. Methods Chromatographic column of HPLC was Ultimate XB-C18. The gradient elution separation was performed on a Ultimate XB-C18 col-umn with a mobile phase of water (containing 2 mmol/L ammonium acetate and 0. 1% formic acid) and methanol (containing 0. 1% formic acid), and temperature of column was 50 ℃, at a speed of 0. 8 mL/min. The way of eluting was gradient. Mass spectrum detection method was ESI positive ion mode, and multiple reaction monitoring (MRM) was used to detect voriconazole ; ionic reaction in quati-tative analysis: mass-to-charge ratio (m/z) 350. 1-281.2, ionic reaction in qualitive analysis: m/z 350. 1-127. 1. Substance Voriconazole-d3 m/z 353.2-284. 2 was used as quantitative ion for Internal standard. Results The standard curve of voriconazole was linear over the range of O. 1-10. 0 μg/ml (r = 0. 9991). The average recovery was among the range of 88%-103% ; intra-day and inter-day vali-dation relative standard deviation (RSDs) were less than 5%. Conclusions This method is convenient, accurate and rapid, and can be used for the determination of voriconazole in clinic test.
作者 王磊 刘红星 Wang Lei;Liu Hongxing(Hebei Yanda Ludaopei Hospital, Sanhe 065201, China)
出处 《中国实用医刊》 2018年第9期30-33,共4页 Chinese Journal of Practical Medicine
关键词 伏立康唑 液质联用 治疗药物监测 Voriconazole HPLC-MS/MS Therapeutic drug monitoring
  • 相关文献

参考文献5

二级参考文献32

  • 1Keady S,Thacker M.Voriconazole in the treatment of in-vasive fungal infections[J].Intensive Crit Care Nurs,2005,21(6):370. 被引量:1
  • 2Ben-Ami R,Lewis RE,Kontoyiannis DP.Immunocompro-mised hosts:immunopharmacology of modern antifungals[J].Clin Infect Dis,2008,47(2):226. 被引量:1
  • 3Purkins L,Wood N,Ghahramani P,et al.Pharmacokinet-ics and safety of voriconazole following intravenous-to oral-dose escalation regimens[J].Antimicrob Agents Che-mother,2002,46(8):2546. 被引量:1
  • 4Purkins L,Wood N,Kleinermans D,et al.Effect of food on the pharmacokinetics of multiple-dose oral voricon-azole[J].Br J Clin Pharmacol,2003,56(Suppl1):17. 被引量:1
  • 5Lazarus HM,Blumer JL,Yanovich S,et al.Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection:a dose escalation study[J].J Clin Pharmacol,2002,42(4):395. 被引量:1
  • 6Walsh TJ,Karlsson MO,Driscoll T,et al.Pharmacoki-netics and safety of intravenous voriconazole in children after single or multiple-dose administration[J].Antimicrob Agents Chemother,2004,48(6):2166. 被引量:1
  • 7Leveque D,Nivoix Y,Jehl F,et al.Clinical pharmacoki-netics of voriconazole[J].Int J Antimicrob Agents,2006,27(4):274. 被引量:1
  • 8Theuretzbacher U,Ihle F,Derendorf H.Pharmacokinetic/pharmacodynamic profile of voriconazole[J].Clin Phar-macokinet,2006,45(7):649. 被引量:1
  • 9Mikus G,Schowel V,Drzewinska M,et al.Potent cyto-chrome P4502C19genotype-related interaction between voriconazole and the cytochrome P4503A4inhibitor rito-navir[J].Clin Pharmacol Ther,2006,80(2):126. 被引量:1
  • 10Moriyama B,Elinoff J,Danner RL,et al.Accelerated metabolism of voriconazole and its partial reversal by ci-metidine[J].Antimicrob Agents Chemother,2009,53(4):1712. 被引量:1

共引文献85

同被引文献13

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部